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Abstract
Background: Long non-coding RNAs (lncRNAs) have been proved to act as key molecules in cancer development
and progression. Dysregulation of lncRNAs is discovered in various tumor tissues and cancer cells where they
can serve as oncogenes or tumor suppressors. Long non-coding RNA HOXD-AS (HOXD cluster antisense RNA 1)
has recently been identified to be involved in the development of several cancers including neuroblastoma,
adenocarcinomas and breast cancer. However, the role of HOXD-AS1 in bladder cancer remains unknown.
Methods: The synthetic tetracycline-controllable shRNA was used to modulate the level of HOXD-AS1 by adding
different concentrations of doxycycline (dox). RT-qPCR was used to detect the expression level of HOXD-AS1. Cell
proliferation was determined by CCK-8 assay and EdU incorporation experiment when HOXD-AS1 was knocked
down. We used wound-healing assay for detecting the effect of HOXD-AS1 on cell migration. Eventually, cell
apoptosis was determined by caspase 3 ELISA assay and flow cytometry assay.
Results: In this study, we found that the expression level of HOXD-AS1 was significantly increased in bladder cancer
tissues and cells. Furthermore, high expression of HOXD-AS1 was significantly related to tumor size, histological grade
and TNM stage. In vitro assays confirmed that knockdown of HOXD-AS1 suppressed cell proliferation/migration and
increased the rate of apoptotic cell in bladder cancer cells. At last, we used the important element of synthetic
biology, tetracycline(tet)-controllable switch, to construct tet-controllable shRNA vectors which can modulate
the expression of HOXD-AS1 in a dosage-dependent manner.
Conclusions: Our research suggested that high expression of HOXD-AS1 may be involved in the bladder cancer
carcinogenesis through inhibiting the phenotypes and activating endogenous cancer-related molecular pathways.
Therefore, HOXD-AS1 may act as an oncogene and provide a potential attractive therapeutic target for bladder
cancer. In addition, the synthetic tetracycline-controllable shRNA may provide a novel method for cancer research
in vitro assays.
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Background
Bladder cancer is a fatal disease with high morbidity and
mortality. It is estimated that 683,310 cases have been
diagnosed in the United States each year. It has become
the fourth most common tumor among men with mor-
bidity almost 4 times than that among women [1].
Approximately 70 % of patients present non-muscle
invasive bladder cancer (NMIBC) and patients with
muscle-invasive bladder cancer (MIBC) account for the
rest [2, 3]. Transurethral resection of bladder tumor
(TURBT) and intravesical chemotherapy usually have
been chosen to treat NMIBC, while radical cystectomy
is used for high-grade muscle-invasive bladder cancer
(MIBC). However, the recurrence rate for NMIBC ranges
from 50 to 70 % and 50 % of MIBC patients died within
5 years despite active treatment [4–7].
Long non-coding RNAs are widely defined as tran-
scripts longer than 200 nucleotides without open reading
frames [8, 9]. Although lncRNAs could not be translated
into proteins, they function as oncogenes or tumor sup-
pressors, and exert important roles in the progression of
malignant tumors [10]. HOXD-AS1 contains eight exons
and its transcript is a novel lncRNA. It is transcribed
from the HOXD cluster on human chromosome 2q31.2
in an antisense manner. HOXD-AS1 is up-regulated in
neuroblastoma, adenocarcinomas and breast cancer.
Moreover, it is closely associated with the progression
and prognosis of these cancers [11–14]. HOXD is the
member of HOX clusters of genes which involves in
regulating embryogenesis and organogenesis. Dysregula-
tion of HOX genes have been found in various cancers.
They act as vital regulators in the processes of methyla-
tion and histone modification [15, 16]. However, there is
no report about the role of HOXD-AS1in bladder cancer.
Synthetic biology combines biological components and
devices from different organisms to design and engineer
artificial biological networks, pathways and systems that
have novel functions and biomedical applications. Con-
veniently, these components can be created or obtained
from different organisms [17–20]. Utilizing medical
synthetic biology to fight against cancer has become a
hot topic in recent years. Base on the principle and
technology of synthetic biology, we used a standard
method to synthesize tetracycline-controllable vectors
which could modulate the expression of target gene in
a dosage-dependent manner. This design provides a
manageable research device to treat bladder cancer.
Here, we reveal the role of HOXD-AS1 in bladder can-
cer. Our data suggests that HOXD-AS1 may serve as an
oncogene in the progression of bladder cancer, and a po-
tential target for the bladder cancer treatments. Further-
more, the tetracycline-controllable shRNA can control
the expression level of HOXD-AS1 in a dose-dependent
manner and inhibit the development of bladder cancer
cells, which may open up a novel way for treating blad-
der cancer.
Methods
Patients and tissue specimens
A total of 50 bladder cancer patients who underwent
partial or radical cystectomy were included in this study.
All specimens were stored in liquid nitrogen immedi-
ately after resection. The diagnosis was based on postop-
erative pathological analysis. The understanding of this
study and written informed consent was received from
each patient. The Institutional Review Board of Shenzhen
Second People’s Hospital has approved this study.
Cell culture
The human bladder cancer cells (5637 and T24) and the
human normal bladder epithelial cells (SV-HUC-1) were
obtained from the Institute of Cell Biology, Chinese
Academy of Sciences (Shanghai, China). The 5637 cells
were grown in RPMI-1640 Medium (Gibco), supple-
mented with 10 % fetal bovine serum (Gibco) at 37 °C in
a 5 % CO2 humidified incubator. The T24 cells were cul-
tured in Dulbecco’s modified Eagle’s medium (Gibco),
supplemented with 10 % fetal bovine serum (Gibco) in a
5 % CO2 humidified incubator at 37 °C. SV-HUC-1 cells
were cultured in F12K medium.
Construction of synthetic tet-controllable shRNA
targeting HOXD-AS1
HOXD-AS1 siRNA (si-HOXD-AS1) was synthesized by
GenePharma, Suzhou, China according to a previous
study. The sequence was GAAAGAAGGACCAAAGTAA
[12]. Negative control siRNA (si-NC) was also provided
from GenePharma. To construct tet-regulatable shRNAs,
the company (FulenGen, Guangzhou, China) inserted the
sequences of the associative tet-inducible shRNA targeting
HOXD-AS1 and the negative control into tetracycline-
inducible plasmid vectorspsi-LVRInU6TGP, respectively.
Cell transfection
When the cells were grown to 40 % confluence in
six-well plates, they were transfected with 200 pmol
si-HOXD-AS1 or si-NC using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the instructions.
However, the cells were transfected with 3 μg plasmid
vectors (tet-controllable HOXD-AS1 shRNA or tet-
controllable NC shRNA) when they got 70 % confluence.
RNA extraction
Total RNA was obtained from the tissues or cells by
using Trizol reagent (Invitrogen, Carlsbad, CA, USA)
according to the instructions. cDNA was transcribed
from 1 μg total RNA using Reverse Transcription Kit
(Takara, Dalian, China). RT-qPCR was performed on the
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ABI7000 system (Applied Biosystems, Foster City, CA,
USA). The reaction system contains 2ul of cDNA, 0.5 μl
of forward primer, 0.5 ul of reverse primer, 5ul of qPCR
Mix(TaKaRa) and 3ul of deionized water. The 2–ΔΔCt
method was chosen to calculate the relative expression
levels. The expression of GAPDH was chosen as the
endogenous control. The primer sequences were listed
as follows: HOXD-AS1 primers forward 5’-GGCTCTT
CCCTAATGTGTGG-3’, reverse: 5’-CAGGTCCAGCAT
GAAACAGA-3’; GAPDH primers forward 5’-CGCTC
TCTGCTCCTCCTGTTC-3’, reverse: 5’- ATCCGTTGA
CTCCGACCTTCAC-3’.
Cell proliferation assays
The CCK-8 assay (TransGen, Beijing, China) was used
to examine cell proliferation. 5 × 103 cells were seeded at
96-well plates at 37 °C for 24 h, and then transfected
with either siRNA or plasmids. After 24, 48, 72 h, 10 μl
CCK-8 was added to the plates and incubated at 37 °C
for 1 h. The absorbance at 450 nm was detected by auto-
matic microplate reader (Bio-Rad, Hercules, CA, USA).
To intuitively observe the proliferative cells, EdU incor-
poration experiment was performed using an EdU assay
kit (Ribobio, Guangzhou, China) according to the manu-
facturer’s instructions.
Wound-healing assay
To explore the effect of HOXD-AS1 on migration in
5637 and T24 cells, we performed the wound-healing
assay. At 48 h post-transfection, we used the yellow pip-
ette tip to scratch a wound field. Then cells were grown
in the medium without fetal bovine serum. The mobi-
lized cells were observed by a digital camera system after
24 h and the migration distance was measured by the
software program HMIAS-2000.
Cell apoptosis assays
Cell apoptosis was determined by caspase 3 ELISA assay
and flow cytometry assay. T24 and 5637 cells were
transfected with siRNAs or plasmids. After incubation
for 48 h, we used the the caspase 3 ELISA assay kit to
detect the activity of caspase 3. A microplate reader was
used to measure the OD values. In order to understand
the accurate rate of apoptotic cellS, we used the flow
cytometry assay. After transfection for 48 h, cells were
collected and then washed by PBS. Besides, cells were
mixed with Annexin V-FITC (AV) and Propidium Iodide
(PI), and incubated in darkness for 15 min. The rate of
apoptotic cells was measured by a flow cytometer
(EPICS, XL-4, Beckman, CA, USA). Each experiment
was repeated at least three times.
Statistical analysis
Each experiment was performed in triplicate. All quanti-
tative data were expressed as mean ± standard deviation
(SD). Statistical analyses were performed by using SPSS
18.0 software (IBM). Statistical significance was tested by
Student’s t-test, Chi square test or ANOVA. P < 0.05 was
considered to be statistically significant.
Results
LncRNA HOXD-AS1 was up-regulated in bladder cancer
tissues and cells, and positively correlated with tumor
size, histological grade and TNM stage
The relative expression level of lncRNA HOXD-AS1 in
50 pairs of matched bladder cancer tissues was examined
by performing real-time qPCR. HOXD-AS1 was signifi-
cantly up-regulated in 60 % (30 of 50) of bladder tumor
tissues (P < 0.001, Fig. 1a, b). Compared with the normal
bladder epithelial cell line SV-HUC1,HOXD-AS1 was
expressed at a higher level in bladder cell lines (P < 0.001
in 5637, P = 0.001 in T24, Fig. 1c, d). These results suggest
that HOXD-AS1 may function as an oncogene in bladder
cancer. We further analyzed the relationship between
HOXD-AS1 and patients’ clinical pathologic factors. As
shown in Table 1, high HOXD-AS1 expression was highly
correlated with tumor size (P = 0.006), histological grade
(P = 0.044), and TNM stage (P = 0.009). However, high
HOXD-AS1 expression was irrelevant with the parameters
including gender, age and lymphatic metastasis. Taken
together, these data indicated that HOXD-AS1 may act
as an oncogene in the progression of bladder cancer.
Knockdown of HOXD-AS1 inhibited bladder cancer cell
proliferation
5637 and T24 cells were transfected with si-HOXD-AS1
or si-NC to investigate whether HOXD-AS1 promotes
proliferation of bladder cancer cells. The relative expres-
sion level of HOXD-AS1 was detected by RT-qPCR at
48 h after transfection. As shown in Fig. 2a, b, the
relative level of HOXD-AS1 in bladder cancer cells was
significantly decreased by si-HOXD-AS1, indicating that
si-HOXD-AS1 transfection was successful (P < 0.001 in
5637, P = 0.002 in T24). The relative expression level of
HOXD-AS1 was reduced by 68.05 % in 5637 cells and
72.08 % in T24 cells. Next, we performed the CCK-8
assay to explore the role of si-HOXD-AS1 in cell proli-
feration. As shown in Fig. 3a, b, the decreased ability of
proliferation was obviously seen in 5637 and T24 cells.
Furthermore, the percentage of EdU positive cells was
decreased significantly after HOXD-AS1 knockdown
(Fig. 4a, b). The percentage of EdU positive cells in si-
HOXD-AS1 group was decreased by 20.29 % in 5637
(P = 0.001) and 25.76 % in T24 (P = 0.001) (Fig. 4c). All
these data suggest that high expression of HOXD-AS1
promoted the proliferation of bladder cancer cells.
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Effects of HOXD-AS1 on cell migration in bladder cancer cells
As shown in Fig. 5a, compared with si-NC group, the
migration capacity was significantly decreased in si-
HOXD-AS1 group. As shown in Fig. 5b, the relative
migration rate in the si-HOXD-AS1 group was de-
clined by 57.83 % in 5637 cells (P < 0.001) and 45.79 %
in T24 cells (P < 0.001). These suggest that silencing
HOXD-AS1 weakened the capacity of migration in
bladder cancer cells.
Knockdown of HOXD-AS1 induced apoptosis
Besides, we assume that knockdown of HOXD-AS1 may
induce apoptosis. The detection of apoptosis was per-
formed by caspase 3 ELISA assay and flow cytometry
assay. As shown in Fig. 6a, b, the activities of caspase 3
in bladder cancer cells were significantly increased after
transfected with si–HOXD-AS1 (P = 0.003 in 5637 and
P = 0.016 in T24). What’s more, the ratio of apoptosis
and early apoptosis fraction in si-HOXD-AS1 trans-
fected cells were greater than the si-NC transfected cells
(Fig. 7a-c, P = 0.001 in 5637 and P < 0.001 in T24). All
these data indicate that high expression of HOXD-AS1
inhibited cell apoptosis in bladder cancer cells.
Tet-controllable HOXD-AS1 shRNA induced by dox
surpressed the expression of HOXD-AS1
Cells were transiently transfected with the plasmids (3 ug)
which expressed the tet-controllable HOXD-AS1 shRNA
or the negative control, respectively. After transfection,
different concentrations of dox (0.01 mg/ml, 0.1 mg/ml
and 1 mg/ml) were added to the cells. As shown in
Fig. 2c, d, the tet-controllable HOXD-AS1 shRNA in-
hibit the relative expression level of HOXD-AS1 in a
Table 1 Correlation between HXOD-AS1 expression and clinical
characteristics of bladder cancer patients





Age(years) <60 31 17 14 0.768
>60 19 12 7
Gender Male 36 19 17 0.537
Female 14 9 5
Tumor size (cm) <3 cm 18 6 12 0.006
≥3 cm 32 24 8
Histological grade Low 22 9 13 0.044
Hight 28 20 8
TNM stage I 29 9 20 0.009
II/III/IV 21 15 6
Lymphatic metastasis N0 44 29 15 0.650
N1 or above 6 5 1
P < 0.05 was considered significant. (Chi-square test was performed)
Fig. 1 Relative HOXD-AS1 expression level in bladder cancer tissues and cells. a A total of 50 bladder cancer patients included in this study were
divided into two groups: the relative low expression group (n = 20) and the relative high expression group (n = 30). b HOXD-AS1 was up-regulated
in bladder cancer tissues compare to matched non tumor tissues (P = 0.002). c, d HOXD-AS1 expression level were higher in 5637 (P < 0.001) and
T24 cells (P = 0.001) than normal human bladder epithelial cells (SV-HUC1)
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Fig. 2 Expression changes of HOXD-AS1 after transfection of siRNA or tet-shRNA. a, b The si-HOXD-AS1 significantly reduced the expression level
of HOXD-AS1 in 5637 (P < 0.001) and T24 (P = 0.002). c, d The tet-shRNA HOXD-AS1 induced by dox regulated the expression of HOXD-AS1 in a
dosage-dependent manner in 5637 (P = 0.008) and T24 cells (P = 0.016)
Fig. 3 Knockdown of HOXD-AS1 by siRNA or tet-shRNA inhibits cell proliferation. CCK-8 assay was performed to investigate the cell growth curve.
a, b Cell proliferation inhibition was detected in 5637 (P < 0.001) and T24 cells (P < 0.001) after transfection with si-HOXD-AS1 (c, d) The tet–shRNA
induced by 1ug/ml dox significantly inhibits cell proliferation in 5637 (P < 0.001) and T24 cells (P < 0.001). Data were expressed as means ± SD
from three independent experiments
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dose-dependent manner. When 1 mg/ml dox was
added into vectors transfected 5637 and T24 cells, the
expression level of HOXD-AS1 was decreased by
54.15 % in 5637 cells (P = 0.008) and 55.54 % in T24
cells (P = 0.016). Therefore, we chose 1 mg/ml as the
best concentration for further study. These results con-
firmed that the tet-controllable HOXD-AS1 shRNA
expressed in bladder cancer cells and inhibited the ex-
pression of HOXD-AS1.
Tet-controllable HOXD-AS1 shRNA inhibited cell
proliferation
To investigate the role of tet-controllable HOXD-AS1
shRNA on cell proliferation in bladder cancer cells,
we performed the CCK-8 and EdU assays. CCK-8 assay
showed that tet-controllable HOXD-AS1 shRNA induced
by dox (1 mg/ml) inhibited cell proliferation significantly
compared with the negative control (Fig. 3c, d). EdU assay
came up with the same results as excepted (Fig. 4d, e).
The percentage of EdU positive cells was reduced by
17.62 % in 5637 cells (P = 0.002) and 23.26 % in T24 cells
(P = 0.002) (Fig. 4f, g). These results confirmed that tet-
controllable HOXD-AS1 shRNA induced by dox could
significantly inhibit cell proliferation.
Tet-controllable HOXD-AS1 shRNA inhibited cell
migration
Wound-healing assay was performed to confirm the
effect of tet-controllable HOXD-AS1 shRNA on the
migration ability in bladder cancer cells. As shown in
Fig. 5c-f, the cells in tet-controllable HOXD-AS1 shRNA
group displayed less migration ability. Compared with
the negative control group, the migration rate of the tet-
controllable HOXD-AS1 shRNA group was decreased by
51.2 % (P < 0.001)in 5637 cells and 39.41 % (P = 0.001) in
T24 cells. These results indicated that tet- controllable
HOXD-AS1 shRNA could strongly inhibit the migration
ability of bladder cancer cells.
Fig. 4 The multiplication capacity of 5637 and T24 cells was declined after transfection with si-HOXD-AS1 or tet-shRNA. EdU assay was performed.
a, b The number of EdU positive cells was decreased significantly after transfected with si-HOXD-AS1 in 5637 and T24 cells. c The percentage of
EDU positive cells in 5637 (P = 0.001) and T24 cells (P = 0.001) can be seen. d, e The number of EdU positive cells was decreased significantly after
transfection with tet-shRNA which was induced by 1ug/ml dox. f, g The percentage of EdU positive cells in 5637 (P = 0.002) and T24 cells (P = 0.002)
can be seen. Data were expressed as means ± SD from three independent experiments
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Tet-controllable HOXD-AS1 shRNA induced cell apoptosis
Finally, we investigated the possible effect of tet-
controllable HOXD-AS1 shRNA on the apoptosis of
bladder cancer cells. Elisa assay was performed to de-
termine the relative activity of caspase-3. As shown in
Fig. 6c, d, the relative activity of caspase-3 was increased
obviously in the tet-controllable HOXD-AS1 shRNA
group (P = 0.001 in 5637 and P = 0.002 in T24). Fur-
thermore, we performed the flow cytometry assay to
explore the apoptosis ratio. As shown in Fig. 7d-g, the
ratio of apoptosis and early apoptosis fraction in the
tet-controllable HOXD-AS1 shRNA group were increased
significantly. Results suggest that the tet-controllable
HOXD-AS1 shRNA could induce apoptosis in bladder
cancer cells (P = 0.001 in 5637 and P < 0.001 in T24).
Discussion
Bladder cancer is a common malignancy, which has
brought great economic burden to the world. The con-
ventional therapy, such as surgery, radiotherapy and
chemical therapy can not improve 5 year survival rate
obviously [21]. Lots of literatures show that numerous
Fig. 5 Silencing HOXD-AS1 inhibited cell migration. a 5637 and T24 cells transfected with si-HOXD-AS1 showed decreased migration capacity
compare with si-NC transfected cells. b The migration rate of 5637 (P < 0.001) and T24 cells (P < 0.001) is shown in the bar chart. c, e. The tet-shRNA
induced by 1ug/ml dox significantly inhibited the migration ability of 5637 and T24. d, f The migration rate of 5637 (P < 0.001) and T24 cells
(P = 0.001) transfected with tet-shRNA were observed. Data were expressed as means ± SD from three independent experiments
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Fig. 6 Knockdown of HOXD-AS1 promotes apoptosis using ELISA assay. a, b Relative activities of caspase-3 in 5637 (P = 0.003) and T24 (P = 0.016)
were shown after transfection with si-HOXD-AS1. c, d The activity of caspase-3 was increased significantly after transfection with tet-shRNA in
5637 (P = 0.001) and T24 cells (P = 0.002). Results represent the mean ± SD from three independent experiments
Fig. 7 Transfection with si-HOXD-AS1 or tet shRNA induced apoptosis in 5637 and T24. a-c The rate of early apoptotic 5637 (P = 0.001) and T24
cells (P < 0.001) were increased significantly after transfection with si-HOXD-AS1. d-g Increased apoptotic cells were observed in tet-shRNA-transfected
5637 (P = 0.001) and T24 cells (P < 0.001). Results represent the mean ± SD from three independent experiments
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lncRNAs involve in the process of tumorigenesis and
tumor progression [22–24]. What’s more, lncRNAs may
serve as tumor markers and therapeutic targets, such as
PVT1, Xist, ATB and MALAT1 [25–28]. HOXD-AS1 is
transcribed from the HOXD gene cluster between
HOXD1 and HOXD3. Besides, HOXD-AS1 is closely
related to HOXD3 expression [11]. High HOXD-AS1
levels are associated with neuroblastoma progression
and regulated by the PI3K/Akt pathway which has been
proved to promote oncogenesis via inhibiting cell apop-
tosis [29]. Furthermore, a series of genes are controlled
by HOXD-AS1 and these genes may serve as biomarkers
of neuroblastoma recurrence and affect the patients’
survival [12]. HOXD-AS1 was also found to be overex-
pressed in adenocarcinomas and breast cancer, and is
characterized as the indicator of poor prognosis [13,
14]. According to our knowledge, the role of HOXD-
AS1 in bladder cancer is still unclear. So, it is neces-
sary to detect the biological function of HOXD-AS1 in
bladder cancer cells.
This is the first study to investigate the function of
HOXD-AS1 in bladder cancer. In this research, we found
that HOXD-AS1 was up-regulated in bladder cancer
tissues and cells, indicating that HOXD-AS1 may act
as an oncogene. Further experiments demonstrate that
HOXD-AS1 may be viewed as a promising tumor maker.
High expression of HOXD-AS1 was positively associ-
ated with clinicopathologic features, including tumor
size, histological grade and TMN stage. To get a better
insight to the function of HOXD-AS1, we silenced
HOXD-AS1 with specific siRNA and found that inhibition
of HOXD-AS1 could inhibit cell proliferation, suppress
cell migration and increase apoptosis in bladder cancer
cells. Significantly, it is the first research to verify the
oncogenic role of HOXD-AS1 in bladder cancer. Further
studies on the modulation of HOXD-AS1 expression and
more thorough molecular mechanisms are needed.
With the rapid development of synthetic biology, more
synthetic gene networks are applied in medical research,
including immuno-regulatory networks and cancer the-
rapy gene circuits [30–32]. Synthetic biological gene
switches including ABA transcriptional switches, tet-on
post-transcriptional switches and hoechst aptamer trans-
lational switches form the basis to engineer novel and
complex gene networks [33–35]. Synthetic tet-on switch
is commonly accepted and is employed to control genes
expression [36, 37]. Inspired by these previous works,
we constructed the synthetic tetracycline-controllable
shRNA targeting HOXD-AS1 and detected its anti-cancer
effects in bladder cancer cells. Our data demonstrated
that the synthetic tetracycline-controllable shRNA target-
ing HOXD-AS1 effectively suppressed the expression level
of HOXD-AS1 in a dose-dependent manner, which subse-
quently inhibited the ability of proliferation/migration and
induced apoptosis in bladder cancer cells. We suppose
that the synthetic tetracycline-controllable shRNA could
control multiple genes expression at the same time and
increasing the transfection efficiency could improve the
efficiency of this device.
It should be noted that there seems to be no signifi-
cant decrease in proliferation between 48 and 72 h in
both T24 and 5637 cells. But the apoptosis assay shows
that there is a significant increase at 48 h. One possible
explanation for these contradictory results is that the
change in proliferation rate may not be readily reflected
by the rate of increase of OD value when the cell num-
ber was continuously increased.
Conclusions
In conclusion, our research suggested that HOXD-AS1
may get involved in the bladder cancer carcinogenesis by
activating endogenous cancer-related molecular pathways.
Therefore, HOXD-AS1 may become a potential and
promising therapeutic target. Furthermore, we use the
synthetic biology component to construct the synthetic
tetracycline-controllable shRNA for controlling the ex-
pression of HOXD-AS1 artificially and inhibiting the
progression of bladder cancer cells. Maybe, it can provide
a novel approach for effectively suppressing specific
oncogenes and promote the development of new anti-
cancer method in the area of medical synthetic biology.
This work may bring a promising future to fight against
bladder cancer.
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